(Reuters) -All doses of Eli Lilly's ( LLY ) weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug Administration's updated shortage list showed on Friday.

Lilly's Mounjaro has been on the U.S. FDA's shortage list since late 2022, while Zepbound was added to the list in April this year.

Surging demand for Mounjaro and Zepbound has led Lilly to invest billions of dollars in boosting their production of these drugs. Danish drugmaker Novo Nordisk, which makes rival drugs Ozempic and Wegovy, is also working to ramp up supply to meet unprecedented demand.

Originally developed for diabetes, GLP-1 therapies have shown to reduce weight by up to 20% in trials. Some analysts estimate that the market for these therapies could hit $150 billion in revenues by the early 2030s.

Several doses of Novo's Ozempic and Wegovy, both chemically known as semaglutide, have been on the U.S. health regulator's shortage list since early 2022.

Currently, all doses of diabetes drug Ozempic are available in the United States, while three doses of Wegovy remain in limited supply.

U.S. Food and Drug Administration typically evaluates the market for a drug, and assesses whether all backorders have been filled for the drug before deciding on whether a shortage has been resolved.

It also verifies whether a drugmaker has built enough safety stock, and checks the ability of alternate manufacturers to cover the demand are also part of the agency's assessment for resolving drug shortages.

Lilly did not immediately respond to a Reuters request for comment.